Is the treatment effect of IFN-β restored after the disappearance of neutralizing antibodies?

Multiple Sclerosis

Volumn 14, Issue 6, 2008, Pages 837-842

  Sorensen, Per Soelberg ^a   Koch Henriksen, Nils ^a,b   Flachs, E M ^c   Bendtzen, K ^a,d   Sellebjerg, Finn ^a   Frederiksen, Jette Lautrup ^e   Jensen, Kai ^f   Heltberg, Anne ^g   Kristensen, Ole ^h   Deth, Sven ⁱ   Madsen, Claus ^j   Stenager, Egon ^k   Petersen, Thor ^l   Sivertsen, Bjarne ^m   Torring, Jesper ⁿ  

^a Rigshospitalet   (Denmark)

^b AALBORG UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^d Biomonitor A/S   (Denmark)

^e GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^f HILLERØD HOSPITAL   (Denmark)

^g ROSKILDE HOSPITAL   (Denmark)

^h Holbaek Hospital

ⁱ NAESTVED HOSPITAL   (Denmark)

^j ODENSE UNIVERSITY HOSPITAL   (Denmark)

^k Vejle Esbjerg and Sonderborg Hospital

^l AARHUS UNIVERSITY HOSPITAL   (Denmark)

^m Viborg Hospital

ⁿ HOLSTEBRO HOSPITAL   (Denmark)

more..

Author keywords

Interferon beta; Interferon beta antibodies; Multiple sclerosis; Neutralizing antibodies; Therapy; Treatment effect

Indexed keywords

BETA INTERFERON; BETA1 INTERFERON; NEUTRALIZING ANTIBODY;

ADULT; ANTIBODY DETECTION; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CONTROLLED STUDY; DRUG EFFICACY; DRUG TREATMENT FAILURE; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; RECURRENCE RISK; TREATMENT DURATION; TREATMENT RESPONSE;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; ANTIBODIES; FEMALE; HUMANS; INTERFERON-BETA; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NEUTRALIZATION TESTS; POISSON DISTRIBUTION; RECURRENCE; TREATMENT OUTCOME;

EID: 48349122841     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458508088942     Document Type: Article

References (30)

1. Ross, C, Clemmesen, KM, Svensor, M, Sorensen, PS, Koch-Henriksen, N, Skovgaard, GL, et al. for the Danish Multiple Sclerosis Study Group. Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Ann Neurol 2000; 48 706-712.
2. Perini, P, Facchinetti, A, Bulian, P, Massaro, AR, Pascalis, DD, Bertolotto, A, et al. Interferon-beta (INF-beta) antibodies in interferon-beta1a- and interferon-beta1b-treated multiple sclerosis patients. Prevalence, kinetics, crossreactivity, and factors enhancing interferon-beta immunogenicity in vivo. Eur Cytokine Netw 2001; 12: 56-61.
3. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655-661.
4. The IFNB Multiple Sclerosis Study Group and The University of British. Columbia MS/MRI Analysis Group. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology 1996; 47: 889-894.
5. PRISMS Study Group. PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 2001; 56: 1628-1636.
6. Francis, GS, Rice, GP, Alsop, JC. Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS. Neurology 2005; 65: 48-55.
7. Polman, C, Kappos, L, White, R, Dahlke, F, Beckmann, K, Pozzilli, C, et al. Neutralizing antibodies during treatment of secondary progressive MS with in erferon beta-1b. Neurology 2003; 60: 37-43.
8. Panitch, H, Miller, A, Paty, D, Weinshenker, B. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology 2004; 63: 1788-1795.
9. Sorensen, PS, Ross, C, Clemmesen, KM, Bendtzen, K, Frederiksen, JL, Jensen, K, et al. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple clerosis. Lancet 2003; 362: 1184-1191.
10. Kappos, L, Clanet, M, Sandberg-Wollheim, M, Radue, EW, Hartung, HP, Hohlfeld, R, et al. Neutralizing antibodies and efficacy of interferon beta-2a: it 4-year controlled study. Neurology 2005; 65: 40-47.
11. Sorensen, PS, Koch-Henriksen, N, Ross, C, Clemmesen, KM, Bendtzen, K. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology 2005; 65: 33-39.
12. Bendtzen, K. Anti-IFN BAb and NAb antibodies: a minireview. Neurology 2003; 61: S6-10.
13. Bertolotto, A, Gilli, F, Sala, A, Audano, L, Castello, A, Magliola, U, et al. Evaluation of bioavailability of three types of IFNbeta in multiple sclerosis patients by a new quantitative-competitive-PCR method for MxA quantification. J Immunol Methods 2001; 256: 141-452.
14. Bertolotto, A, Gilli, F, Sala, A, Capobianco, M, Malucchi, S, Milano, E, et al. Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients. Neurology 2003; 60: 634-639.
15. Bertolotto, A, Sala, A, Malucchi, S. Marnetto, F, Caldano, M, Di Sapio, A, et al. Biological activity of interferon betas in patients with multiple sclerosis is affected by treatment regimen and neutralising antibodies. J Neurol Neurosurg Psychiatry 2004; 75: 1294-1299.
16. Cook, SD, Quinless, JR, Jotkowitz, A, Beaton, P. Serum IFN neutralizing antibodies and neopterin levels in a cross- section of MS patients. Neurology 2001; 57: 1080-1084.
17. Deisenhammer, F, Reindl, M, Harvey, J. Gasse, T, Dilitz, E, Berger, T. Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies. Neurology 1999; 52: 1239-1243.
18. Pachner, AR, Bertolotto, A, Deisenhammmer, F. Measurement of MxA mRNA or protein as a biomarker of IFNbeta bioactivity: detection of antibody-mediated decreased bioactivity (ADB). Neurology 2003; 61: S24-S26.
19. Pachner, AR, Dail, D, Pak, E, Narayan, K. The importance of measuring IFNbeta bioactivity: monitoring in MS patients and the effect of anti-IFNbeta antibodies. J Neuroimmunol 2005; 166: 180-188.
20. Rudick, RA, Simonian, NA, Alam, JA, Campion, M, Scaramucci, JO, Jones, W, et al. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 1998; 50: 1266-1272.
21. Sorensen, PS, Tscherning T, Mathiesen, HK, Langkilde, AR, Ross, C, Ravnborg, M, et al. Neutralizing antibodies hamper IFNbeta bioactivity and treatment effect on MRI in patients with MS, Neurology 2006; 67: 1681-1683.
22. Polman, CH, Kappos, L, Petkau, J, Thompson, A. Neutralising antibodies to interferon beta during the treatment of multiple sclerolis. J. Neurol Neurosurg Pscyhiatry 74: 1162-11611
23. Sorensen, PS, Delsenhammer, F, Duda, P, Hohlfeld, R, Myhr, KM, Palace, J, et al. Guidelines on use of anti-interferon-beta antibody measurements in multiple sclerosis - report of an EFM Task Force on IFN-beta antibodies in multiple sclerosis. Eur J Neurol 2005; 12: 817-827.
24. Malucchi, S, Capobianco, M, Gilli, F, Marnetto, F, Caldano, M, Sala, A, et al. Fate of multiple sclerosis patients positive for neutralising antibodies towards interferon beta shifted to alternative treatments. Neurol Sci 2005; 26: S213-S214.
25. Petkau, AJ, White, R. Statistical approaches to assessing the effects of neutralizing antibodies IFNbeta-1b in the pivotal trial of relapsing-remitting multiple. sclerosis. Neurology 2003; 61: S35-S37.
26. Petkau, AJ, White, RA, Ebers, GC, Reder, AT, Sibley, WA, Lublin, FP, et al. Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis. Mult Scler 2004; 10: 126-138.
27. Sorensen, PS, Koch-Henriksen, N, Ravnborg, M, Frederiksen, JL, Jensen, K, Heltberg, A, et al. Immunomodulatory treatment of multiple aclerosis in Denmark: a prospective nationwide survey. Mult Scler 2006; 12: 253-264.
28. Bellomi, F, Scagnolari, C, Tomassini, V, Gasperini, C, Paolillo, A, Pozzilli, C, et al. Fate of neutralizing and binding antibodies to IFN beta in MS patients treated with IFN beta for 6 years. J Neurol Sci 2003; 215: 3-8.
29. Gneiss C, Reindl, M, Lutterotti, A, Ihling, R, Egg, R, Khalil, M, et al. Interferon-beta the neutralizing antibody (NAb) titre predicts reversion to NAb negativity. Mult Scler 2004; 10: 507-510.
30. Sorensen, PS, Koch-Henriksen, N, Bendtzen, K. Are ex Vivo neutralising antibodies against IFN-β always detrimental to therapeutic efficacy in multiple sclerosis? Mult Scler 2007; 13: 616-621.